Analyst: Genmab hope could hit the market this year
Genmab’s major drug hope, daratumumab, could be ready for launch on the US market this year, following FDA’s decision to accept an application for the drug for review.
BY STEFAN SINGH KAILAY
Late last week, the Danish-based biotech group Genmab and its US-based partner Janssen announced that it had initiated a rolling submission of a new application for cancer drug daratumumab, which is seen as Genmab’s most important asset.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Nordea: Analysts overlook daratumumab’s potential
For abonnenter
Danske: Genmab partner might accelerate launch
For abonnenter
Increased belief in Genmab’s potential blockbuster
For abonnenter
